Hepatotoxicity induced by “the 3Ks”: Kava, kratom and khat

International Journal of Molecular Sciences

Volumn 17, Issue 4, 2016, Pages

  Pantano, Flaminia ^a   Tittarelli, Roberta ^a   Mannocchi, Giulio ^a   Zaami, Simona ^a   Ricci, Serafino ^a   Giorgetti, Raffaele ^b   Terranova, Daniela ^a   Busardò, Francesco P ^a   Marinelli, Enrico ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Hepatotoxicity; Herb induced liver injury; Herbals; Kava; Khat; Kratom

Indexed keywords

7 HYDROXYMITRAGYNINE; ALKALOID DERIVATIVE; CATHA EDULIS EXTRACT; CATHINONE; CYTOCHROME P450; DEMETHOXYYANGONIN; DIHYDROKAWAIN; DIHYDROMETHYSTICIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; KAVA; KAWAIN; LIVER ENZYME; MERUCATHINE; MERUCATHINONE; METHYSTICIN; MITRAGYNINE; NOREPHEDRINE; PAYNANTHEINE; PIPERMETHYSTINE; PLANT MEDICINAL PRODUCT; SPECIOCILIATINE; SPECIOGYNINE; UNCLASSIFIED DRUG; YANGONIN; PLANT EXTRACT;

CELL DEGENERATION; CLINICAL TRIAL (TOPIC); ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; LIVER TOXICITY; META ANALYSIS (TOPIC); METABOLITE; MITRAGYNA; MITRAGYNA SPECIOSA; MUTATION; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; CATHA; CHEMISTRY; DRUG EFFECTS; LIVER; MEDICINAL PLANT; PATHOLOGY; PIPER (PLANT); TOXICITY;

ANIMALS; CATHA; HUMANS; LIVER; MITRAGYNA; PIPER; PLANT EXTRACTS; PLANTS, MEDICINAL;

EID: 84963774459     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17040580     Document Type: Review

References (181)

1. Teschke, R.; Frenzel, C.; Glass, X.; Schulze, J.; Eickhoff, A. Herbal hepatotoxicity: A critical review. Br. J. Clin. Pharmacol. 2013, 75, 630–636. [CrossRef] [PubMed]
2. Teschke, R.; Frenzel, C.; Schulze, J.; Eickhoff, A. Herbal hepatotoxicity: Challenges and pitfalls of causality assessment methods. World J. Gastroenterol. 2013, 19, 2864–2882. [CrossRef] [PubMed]
3. Teschke, R.;Wolff, A. Kava hepatotoxicity: Regulatory data selection and causality assessment. Dig. Liver Dis. 2009, 41, 891–901. [CrossRef] [PubMed]
4. Danan, G.; Teschke, R. RUCAM in drug and herb induced liver injury: The update. Int. J. Mol. Sci. 2015, 17.[CrossRef]
5. Teschke, R.; Genthner, A.; Wolff, A.; Frenzel, C.; Schulze, J.; Eickhoff, A. Herbal hepatotoxicity: Analysis of cases with initially reported positive re-exposure tests. Dig. Liver Dis. 2014, 46, 264–269. [CrossRef]
6. Showman, A.F.; Baker, J.D.; Linares, C.; Naeole, C.K.; Borris, R.; Johnston, E.; Konanui, J.; Turner, H. Contemporary Pacific andWestern perspectives onawa (Piper methysticum) toxicology. Fitoterapia 2015, 100, 56–67. [CrossRef] [PubMed]
7. Shimoda, L.M.; Park, C.; Stokes, A.J.; Gomes, H.H.; Turner, H. Pacific island 1Awa (Kava) extracts, but not isolated kavalactones, promote proinflammatory responses in model mast cells. Phytother. Res. 2012, 26, 1934–1941. [CrossRef] [PubMed]
8. Li, X.Z.; Ramzan, I. Role of ethanol in kava hepatotoxicity. Phytother. Res. 2010, 24, 475–480. [CrossRef] [PubMed]
9. Faolex. Available online: http://faolex.fao.org/docs/html/van38473.htm (accessed on 19 December 2015).
10. Teschke, R.; Schulze, J. Risk of kava hepatotoxicity and the FDA consumer advisory. JAMA 2010, 304, 2174–2175. [CrossRef] [PubMed]
11. Ehtpa. Available online: http://www.ehtpa.eu/pdf/EWG%20on%20Kava,%20Jul06.pdf (accessed on 29 January 2015).
12. Olsen, L.R.; Grillo, M.P.; Skonberg, C. Constituents in kava extracts potentially involved in hepatotoxicity: A review. Chem. Res. Toxicol. 2011, 24, 992–1002. [CrossRef] [PubMed]
13. Singh, Y.N. Kava: An overview. J. Ethnopharmacol. 1992, 37, 13–45. [CrossRef]
14. Moulds, R.F.; Malani, J. Kava: Herbal panacea or liver poison? Med. J. Aust. 2003, 178, 451–453. [PubMed]
15. Mathews, J.D.; Riley, M.D.; Fejo, L.; Munoz, E.; Milns, N.R.; Gardner, I.D.; Powers, J.R.; Ganygulpa, E.; Gununuwawuy, B.J. Effects of the heavy usage of kava on physical health: Summary of a pilot survey in an aboriginal community. Med. J. Aust. 1988, 148, 548–555. [PubMed]
16. Clough, A.R.; Jacups, S.P.; Wang, Z.; Burns, C.B.; Bailie, R.S.; Cairney, S.J.; Collie, A.; Guyula, T.; McDonald, S.P.; Currie, B.J. Health effects of kava use in an eastern Arnhem Land Aboriginal community. Intern. Med. J. 2003, 33, 336–340. [CrossRef] [PubMed]
17. Young, M.C.; Fricker, P.A.; Thomson, N.J.; Lee, K.A. Sudden death due to ischaemic heart disease in young aboriginal sportsmen in the Northern Territory, 1982–1996. Med. J. Aust. 1999, 170, 425–428. [PubMed]
18. Weeramanthri, T.; Spillane, P.; Currie, B. Kava and Sudden Cardiac Death. In Kava Research Workshop, Proceedings of a Workshop Convened by the Miwatj Health Aboriginal Corporation, Nhulunbuy, Australia, 10–11 May 1994.
19. Bilia, A.R.; Gallon, S.; Vincieri, F.F. Kava-kava and anxiety: Growing knowledge about the efficacy and safety. Life Sci. 2002, 70, 2581–2597. [CrossRef]
20. World Health Organization. Assessments of the Risk of Hepatotoxicity with Kava Products; WHO Document Production Services: Geneva, Switzerland, 2007.
21. Teschke, R.; Genthner, A.;Wolff, A. Kava hepatotoxicity: Comparison of aqueous, ethanolic, acetonic kava extracts and kava-herbs mixtures. J. Ethnopharmacol. 2009, 123, 378–384. [CrossRef] [PubMed]
22. Teschke, R.; Sarris, J.; Lebot, V. Kava hepatotoxicity solution: A six-point plan for new kava standardization. Phytomedicine 2011, 18, 96–103. [CrossRef] [PubMed]
23. Teschke, R.; Sarris, J.; Schweitzer, I. Kava hepatotoxicity in traditional and modern use: The presumed Pacific kava paradox hypothesis revisited. Br. J. Clin. Pharmacol. 2012, 73, 170–174. [CrossRef] [PubMed]
24. Ahpa. Available online: http://ventquery.com/1975428.html (accessed on 13 March 2016).
25. Lebot, V. The Quality of Kava Consumed in the South Pacific. HerbalGram 2006, 71, 34–37. Available online: https://ewsd.wiv-isp.be/Publications%20on%20new%20psychoactive%20substances/Kava/Lebot2006_kava-quality-control.pdf (accessed on 13 March 2016).
26. Sorrentino, L.; Capasso, A.; Schmidt, M. Safety of ethanolic kava extract: Results of a study of chronic toxicity in rats. Phytomedicine 2006, 13, 542–549. [CrossRef] [PubMed]
27. Stickel, F.., Letter to the editor “Genetic polymorphisms in the UDP-glucuronosyltransferase UGT1A7 gene in patients with acute liver failure after kava-kava consumption”. Arch. Toxicol. 2015, 489, 2175–2176. [CrossRef] [PubMed]
28. Strahl, S.; Ehret, V.; Dahm, H.H.; Maier, K.P. Necrotizing hepatitis after taking herbal remedies. Dtsch. Med. Wochenschr. 1998, 123, 1410–1414. [CrossRef] [PubMed]
29. FDA. Available online: http://www.fda.gov/Food/ResourcesForYou/Consumers/ucm085482.htm (accessed on 19 December 2015).
30. CDC. Available online: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5147a1.htm (accessed on 30 November 2015).
31. Gazzetta Ufficiale. Available online: http://www.gazzettaufficiale.it/atto/vediMenuHTML;jsessionid=UQJ6BSGTdfr4T2No+AmHzg__ntc-as1-guri2b?atto.dataPubblicazioneGazzetta=2002-06-18&atto.codiceRedazionale=02A07856&tipoSerie=serie_generale&tipoVigenza=originario (accessed on 19 December 2015).
32. Hassan, Z.; Muzaimi, M.; Navaratnam, V.; Yusoff, N.H.; Suhaimi, F.W.; Vadivelu, R.; Vicknasingam, B.K.; Amato, D.; von Horsten, S.; Ismail, N.I.; et al. From Kratom to mitragynine and its derivatives: Physiological and behavioural effects related to use, abuse, and addiction. Neurosci. Biobehav. Rev. 2013, 37, 138–151.[CrossRef] [PubMed]
33. Jansen, K.L.; Prast, C.J. Ethnopharmacology of kratom and the Mitragyna alkaloids. J. Ethnopharmacol. 1988, 23, 115–119. [CrossRef]
34. Ingsathit, A.; Woratanarat, P.; Anukarahanonta, T.; Rattanasiri, S.; Chatchaipun, P.; Wattayakorn, K.; Lim, S.; Suriyawongpaisal, P. Prevalence of psychoactive drug use among drivers in Thailand: A roadside survey. Accid. Anal. Prev. 2009, 41, 474–478. [CrossRef] [PubMed]
35. Maruyama, T.; Kawamura, M.; Kikura-Hanajiri, R.; Takayama, H.; Goda, Y. The botanical origin of kratom (Mitragyna speciosa; Rubiaceae) available as abused drugs in the Japanese markets. J. Nat. Med. 2009, 63, 340–344. [CrossRef] [PubMed]
36. Adkins, J.E.; Boyer, E.W.; McCurdy, C.R. Mitragyna speciosa, a psychoactive tree from Southeast Asia with opioid activity. Curr. Top. Med. Chem. 2011, 11, 1165–1175. [CrossRef] [PubMed]
37. Warner, M.L.; Kaufman, N.C.; Grundmann, O. The pharmacology and toxicology of kratom: From traditional herb to drug of abuse. Int. J. Legal Med. 2016, 130, 127–138. [CrossRef] [PubMed]
38. Shellard, E.J. Ethnopharmacology of kratom and the Mitragyna alkaloids. J. Ethnopharmacol. 1989, 25, 123–124. [CrossRef]
39. Gong, F.; Gu, H.; Xu, Q.; Kang, W. Genus Mitragyna: Ethnomedicinal uses and pharmacological studies. Phytopharmacology 2012, 3, 263–272.
40. Suwanlert, S. A study of kratom eaters in Thailand. Bull. Narc. 1975, 27, 21–27. [PubMed]
41. Vicknasingam, B.; Narayanan, S.; Beng, G.T.; Mansor, S.M. The informal use of ketum (Mitragyna speciosa) for opioid withdrawal in the northern states of peninsular Malaysia and implications for drug substitution therapy. Int. J. Drug Policy 2010, 21, 283–288. [CrossRef] [PubMed]
42. Prozialeck, W.C.; Jivan, J.K.; Andurkar, S.V. Pharmacology of kratom: An emerging botanical agent with stimulant, analgesic and opioid-like effects. J. Am. Osteopath. Assoc. 2012, 112, 792–799. [PubMed]
43. Burkill, I.H.; Birtwistle, W.; Foxworthy, F.W.; Scrivenor, J.B.; Watson, J.B. A Dictionary of the Economic Products of the Malay peninsula; Oxford University Press: London, UK, 1935; Volume 2, pp. 1480–1483.
44. Wray, L. Biak: An opium substitute. J. Fed. Malay States Mus. 1907, 2, 53.
45. Harizal, S.N.; Mansor, S.M.; Hasnan, J.; Tharakan, J.K.; Abdullah, J. Acute toxicity study of the standardized methanolic extract of Mitragyna speciosa Korth in rodent. J. Ethnopharmacol. 2010, 131, 404–409. [CrossRef] [PubMed]
46. Hillebrand, J.; Olszewski, D.; Sedefov, R. Legal highs on the Internet. Subst. Use Misuse 2010, 45, 330–340.[CrossRef] [PubMed]
47. Arndt, T.; Claussen, U.; Gussregen, B.; Schrofel, S.; Sturzer, B.; Werle, A.; Wolf, G. Kratom alkaloids and O-desmethyltramadol in urine of a “Krypton” herbal mixture consumer. Forensic Sci. Int. 2011, 208, 47–52.[CrossRef] [PubMed]
48. Ulbricht, C.; Costa, D.; Dao, J.; Isaac, R.; LeBlanc, Y.C.; Rhoades, J.; Windsor, R.C. An evidence-based systematic review of kratom (Mitragyna speciosa) by the Natural Standard Research Collaboration. J. Diet. Suppl. 2013, 10, 152–170. [CrossRef] [PubMed]
49. Kronstrand, R.; Roman, M.; Thelander, G.; Eriksson, A. Unintentional fatal intoxications with mitragynine and O-desmethyltramadol from the herbal blend Krypton. J. Anal. Toxicol. 2011, 35, 242–247. [CrossRef] [PubMed]
50. Tungtananuwat, W.; Lawanprasert, S. Fatal 4 _ 100; home-made kratom juice cocktail. J. Health Res. 2010, 24, 43–47.
51. Kowalczuk, A.P.; Lozak, A.; Zjawiony, J.K. Comprehensive methodology for identification of Kratom in police laboratories. Forensic Sci. Int. 2013, 233, 238–243. [CrossRef] [PubMed]
52. Raffa, R.B. Kratom and Other Mitragynines: The Chemistry and Pharmacology of Opioids from a Non-Opium Source; CRC Press Taylor & Francis Group: Boca Raton, FL, USA, 2014.
53. Sabetghadam, A.; Ramanathan, S.; Sasidharan, S.; Mansor, S.M. Subchronic exposure to mitragynine, the principal alkaloid of Mitragyna speciosa, in rats. J. Ethnopharmacol. 2013, 146, 815–823. [CrossRef] [PubMed]
54. Kapp, F.G.; Maurer, H.H.; Auwarter, V.; Winkelmann, M.; Hermanns-Clausen, M. Intrahepatic cholestasis following abuse of powdered kratom (Mitragyna speciosa). J. Med. Toxicol. 2011, 7, 227–231. [CrossRef] [PubMed]
55. Erowid. Available online: https://www.erowid.org/plants/kratom/kratom_health.shtml (accessed on 28 December 2015).
56. El-Menyar, A.; Mekkodathil, A.; Al-Thani, H.; Al-Motarreb, A. Khat use: History and heart failure. Oman Med. J. 2015, 30, 77–82. [CrossRef] [PubMed]
57. Patel, N.B. “Natural Amphetamine” Khat: A cultural tradition or a drug of abuse? Int. Rev. Neurobiol. 2015, 120, 235–255. [PubMed]
58. Balint, E.E.; Falkay, G.; Balint, G.A. Khat—A controversial plant. Wien. Klin. Wochenschr. 2009, 121, 604–614.[CrossRef] [PubMed]
59. Toennes, S.W.; Harder, S.; Schramm, M.; Niess, C.; Kauert, G.F. Pharmacokinetics of cathinone, cathine and norephedrine after the chewing of khat leaves. Br. J. Clin. Pharmacol. 2003, 56, 125–130. [CrossRef] [PubMed]
60. Murray, C.D.; Le Roux, C.W.; Emmanuel, A.V.; Halket, J.M.; Przyborowska, A.M.; Kamm, M.A.; Murray-Lyon, I.M. The effect of Khat (Catha edulis) as an appetite suppressant is independent of ghrelin and PYY secretion. Appetite 2008, 51, 747–750. [CrossRef] [PubMed]
61. Girma, T.; Mossie, A.; Getu, Y. Association between body composition and khat chewing in Ethiopian adults. BMC Res. Notes 2015, 8, 680. [CrossRef] [PubMed]
62. Al-Habori, M. The potential adverse effects of habitual use of Catha edulis (khat). Expert Opin. Drug Saf. 2005, 4, 1145–1154. [CrossRef] [PubMed]
63. Pateria, P.; de Boer, B.; MacQuillan, G. Liver abnormalities in drug and substance abusers. Best Pract. Res. Clin. Gastroenterol. 2013, 27, 577–596. [CrossRef] [PubMed]
64. Riyaz, S.; Imran, M.; Gleeson, D.; Karajeh, M.A. Khat (Catha edulis) as a possible cause of autoimmune hepatitis. World J. Hepatol. 2014, 6, 150–154. [CrossRef] [PubMed]
65. Roelandt, P.; George, C.; d’Heygere, F.; Aerts, R.; Monbaliu, D.; Laleman, W.; Cassiman, D.; Verslype, C.; van Steenbergen, W.; Pirenne, J.; et al. Acute liver failure secondary to khat (Catha edulis)-induced necrotic hepatitis requiring liver transplantation: Case report. Transpl. Proc. 2011, 43, 3493–3495. [CrossRef] [PubMed]
66. Yildiz, H.; Komuta, M.; Monsalve, C.; Starkel, P.; Lefebvre, C. To chew or not to chew: That’s the question. Acta Clin. Belg. 2015. [CrossRef] [PubMed]
67. Soboka, M.; Tesfaye, M.; Feyissa, G.T.; Hanlon, C. Khat use in people living with HIV: A facility-based cross-sectional survey from South West Ethiopia. BMC Psychiatry 2015, 15, 69. [CrossRef] [PubMed]
68. Ketema, T.; Yohannes, M.; Alemayehu, E.; Ambelu, A. Effect of chronic khat (Catha edulis, Forsk) use on outcome of Plasmodium berghei ANKA infection in Swiss albino mice. BMC Infect. Dis. 2015, 15, 170.[CrossRef] [PubMed]
69. Ketema, T.; Bacha, K.; Alemayehu, E.; Ambelu, A. Incidence of severe malaria syndromes and status of immune responses among Khat chewer Malaria patients in Ethiopia. PLoS ONE 2015, 10, e0131212.[CrossRef] [PubMed]
70. Teschke, R.; Qiu, S.X.; Lebot, V. Herbal hepatotoxicity by kava: Update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culprits. Dig. Liver Dis. 2011, 43, 676–681. [CrossRef] [PubMed]
71. Whitton, P.A.; Lau, A.; Salisbury, A.; Whitehouse, J.; Evans, C.S. Kava lactones and the kava-kava controversy. Phytochemistry 2003, 64, 673–679. [CrossRef]
72. Clouatre, D.L. Kava kava: Examining new reports of toxicity. Toxicol. Lett. 2004, 150, 85–96. [CrossRef] [PubMed]
73. Denham, A.; McIntyre, M.; Whitehouse, J. Kava—The unfolding story: Report on a work-in-progress. J. Altern. Complement. Med. 2002, 8, 237–263. [CrossRef] [PubMed]
74. Dragull, K.; Yoshida, W.Y.; Tang, C.S. Piperidine alkaloids from Piper methysticum. Phytochemistry 2003, 63, 193–198. [CrossRef]
75. Siméoni, P.; Lebot, V. Identification of factors determining kavalactones content and chemotype in Kava (Piper methysticum Forst. f). Biochem. Syst. Ecol. 2002, 30, 413–424. [CrossRef]
76. Rowe, A.; Zhang, L.Y.; Ramzan, I. Toxicokinetics of kava. Adv. Pharmacol. Sci. 2011, 2011. [CrossRef] [PubMed]
77. Leon, F.; Habib, E.; Adkins, J.E.; Furr, E.B.; McCurdy, C.R.; Cutler, S.J. Phytochemical characterization of the leaves of Mitragyna speciosa grown in U.S.A. Nat. Prod. Commun. 2009, 4, 907–910. [PubMed]
78. Takayama, H. Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciosa. Chem. Pharm. Bull. 2004, 52, 916–928. [CrossRef] [PubMed]
79. Matsumoto, K.; Horie, S.; Ishikawa, H.; Takayama, H.; Aimi, N.; Ponglux, D.; Watanabe, K. Antinociceptive effect of 7-hydroxymitragynine in mice: Discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa. Life Sci. 2004, 74, 2143–2155. [CrossRef] [PubMed]
80. Hooper, D. The anti-opium leaf. Pharm. J. 1907, 78, 453.
81. Zacharias, D.E.; Rosenstein, R.D.; Jeffrey, E.A. The structure of mitragynine hydroiodide. Acta Crystallogr. 1965, 18, 1039–1043. [CrossRef]
82. Matsumoto, K.; Mizowaki, M.; Suchitra, T.; Takayama, H.; Sakai, S.; Aimi, N.; Watanabe, H. Antinociceptive action of mitragynine in mice: Evidence for the involvement of supraspinal opioid receptors. Life Sci. 1996, 59, 1149–1155. [CrossRef]
83. Watanabe, K.; Yano, S.; Horie, S.; Yamamoto, L.T. Inhibitory effect of mitragynine, an alkaloid with analgesic effect from Thai medicinal plant Mitragyna speciosa, on electrically stimulated contraction of isolated guinea-pig ileum through the opioid receptor. Life Sci. 1997, 60, 933–942. [CrossRef]
84. Rosenbaum, C.D.; Carreiro, S.P.; Babu, K.M. Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. J. Med. Toxicol. 2012, 8, 15–32. [CrossRef] [PubMed]
85. Matsumoto, K.; Hatori, Y.; Murayama, T.; Tashima, K.; Wongseripipatana, S.; Misawa, K.; Kitajima, M.; Takayama, H.; Horie, S. Involvement of mu-opioid receptors in antinociception and inhibition of gastrointestinal transit induced by 7-hydroxymitragynine, isolated from Thai herbal medicine Mitragyna speciosa. Eur. J. Pharmacol. 2006, 549, 63–70. [CrossRef] [PubMed]
86. Kitajima, M.; Misawa, K.; Kogure, N.; Said, I.M.; Horie, S.; Hatori, Y.; Murayama, T.; Takayama, H. A new indole alkaloid, 7-hydroxyspeciociliatine, from the fruits of Malaysian Mitragyna speciosa and its opioid agonistic activity. J. Nat. Med. 2006, 60, 28–35. [CrossRef]
87. Erowid. Available online: https://www.erowid.org/plants/kratom/kratom_dose.shtml (accessed on 2 January 2016).
88. European Monitoring Center for Drugs and Drug Addiction. Available online: http://www.emcdda.europa.eu/publications/drug-profiles/kratom (accessed on 2 January 2016).
89. Matsumoto, K.; Horie, S.; Takayama, H.; Ishikawa, H.; Aimi, N.; Ponglux, D.; Murayama, T.; Watanabe, K. Antinociception, tolerance and withdrawal symptoms induced by 7-hydroxymitragynine, an alkaloid from the Thai medicinal herb Mitragyna speciosa. Life Sci. 2005, 78, 2–7. [CrossRef] [PubMed]
90. Kong, W.M.; Chik, Z.; Ramachandra, M.; Subramaniam, U.; Aziddin, R.E.; Mohamed, Z. Evaluation of the effects of Mitragyna speciosa alkaloid extract on cytochrome P450 enzymes using a high throughput assay. Molecules 2011, 16, 7344–7356. [CrossRef] [PubMed]
91. Boyer, E.W.; Babu, K.M.; Adkins, J.E.; McCurdy, C.R.; Halpern, J.H. Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa Korth). Addiction 2008, 103, 1048–1050. [CrossRef] [PubMed]
92. Holler, J.M.; Vorce, S.P.; McDonough-Bender, P.C.; Magluilo, J., Jr.; Solomon, C.J.; Levine, B. A drug toxicity death involving propylhexedrine and mitragynine. J. Anal. Toxicol. 2011, 35, 54–59. [CrossRef] [PubMed]
93. Nelsen, J.L.; Lapoint, J.; Hodgman, M.J.; Aldous, K.M. Seizure and coma following Kratom (Mitragynina speciosa Korth) exposure. J. Med. Toxicol. 2010, 6, 424–426. [CrossRef] [PubMed]
94. Neerman, M.F.; Frost, R.E.; Deking, J. A drug fatality involving Kratom. J. Forensic Sci. 2013, 58 (Suppl. S1), S278–S279. [CrossRef] [PubMed]
95. Dorman, C.; Wong, M.; Khan, A. Cholestatic hepatitis from prolonged kratom use: A case report. Hepatology 2015, 61, 1086–1087. [CrossRef] [PubMed]
96. Kite, G.C.; Ismail, M.; Simmonds, M.S.; Houghton, P.J. Use of doubly protonated molecules in the analysis of cathedulins in crude extracts of khat (Catha edulis) by liquid chromatography/serial mass spectrometry. Rapid Commun. Mass Spectrom. 2003, 17, 1553–1564. [CrossRef] [PubMed]
97. Wabe, N.T. Chemistry, pharmacology, and toxicology of khat (Catha edulis forsk): A review. Addict. Health 2011, 3, 137–149. [PubMed]
98. Groves, R.A.; Hagel, J.M.; Zhang, Y.; Kilpatrick, K.; Levy, A.; Marsolais, F.; Lewinsohn, E.; Sensen, C.W.; Facchini, P.J. Transcriptome profiling of khat (Catha edulis) and Ephedra sinica reveals gene candidates potentially involved in amphetamine-type alkaloid biosynthesis. PLoS ONE 2015, 10, e0119701. [CrossRef] [PubMed]
99. Hagel, J.M.; Krizevski, R.; Kilpatrick, K.; Sitrit, Y.; Marsolais, F.; Lewinsohn, E.; Facchini, P.J. Expressed sequence tag analysis of khat (Catha edulis) provides a putative molecular biochemical basis for the biosynthesis of phenylpropylamino alkaloids. Genet. Mol. Biol. 2011, 34, 640–646. [PubMed]
100. Krizevski, R.; Dudai, N.; Bar, E.; Lewinsohn, E. Developmental patterns of phenylpropylamino alkaloids accumulation in khat (Catha edulis, Forsk.). J. Ethnopharmacol. 2007, 114, 432–438. [CrossRef] [PubMed]
101. Kalix, P.; Braenden, O. Pharmacological aspects of the chewing of khat leaves. Pharmacol. Rev. 1985, 37, 149–164. [PubMed]
102. UN. Étude sûr la Composition Chimique du Khat: Recherches sûr la Fraction Phenylalkylamine; UN Document MNAR/11/1975; United Nations: New York, NY, USA, 1975.
103. Russmann, S.; Barguil, Y.; Cabalion, P.; Kritsanida, M.; Duhet, D.; Lauterburg, B.H. Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia. Eur. J. Gastroenterol. Hepatol. 2003, 15, 1033–1036.[CrossRef] [PubMed]
104. Rychetnik, L.; Madronio, C.M. The health and social effects of drinking water-based infusions of kava: A review of the evidence. Drug Alcohol Rev. 2011, 30, 74–83. [CrossRef] [PubMed]
105. Clough, A. Enough! Or too much. What is “excessive” kava use in Arnhem Land? Drug Alcohol Rev. 2003, 22, 43–51. [CrossRef] [PubMed]
106. Brown, A.C.; Onopa, J.; Holck, P.; Kaufusi, P.; Kabasawa, D.; Craig, W.J.; Dragull, K.; Levine, A.M.; Baker, J.D. Traditional kava beverage consumption and liver function tests in a predominantly Tongan population in Hawaii. Clin. Toxicol. 2007, 45, 549–556. [CrossRef] [PubMed]
107. Pittler, M.H.; Ernst, E. Kava extract for treating anxiety. Cochrane Database Syst. Rev. 2003, 195, CD003383.
108. Sarris, J.; Kavanagh, D.J.; Byrne, G.; Bone, K.M.; Adams, J.; Deed, G. The Kava Anxiety Depression Spectrum Study (KADSS): A randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. Psychopharmacology 2009, 205, 399–407. [CrossRef] [PubMed]
109. Sarris, J.; Stough, C.; Teschke, R.; Wahid, Z.T.; Bousman, C.A.; Murray, G.; Savage, K.M.; Mouatt, P.; Ng, C.; Schweitzer, I. Kava for the treatment of generalized anxiety disorder RCT: Analysis of adverse reactions, liver function, addiction, and sexual effects. Phytother. Res. 2013, 27, 1723–1728. [CrossRef] [PubMed]
110. Nerurkar, P.V.; Dragull, K.; Tang, C.S. In vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactones. Toxicol. Sci. 2004, 79, 106–111. [CrossRef] [PubMed]
111. DiSilvestro, R.A.; Zhang, W.; DiSilvestro, D.J. Kava feeding in rats does not cause liver injury nor enhance galactosamine-induced hepatitis. Food Chem. Toxicol. 2007, 45, 1293–1300. [CrossRef] [PubMed]
112. Lechtenberg, M.; Quandt, B.; Schmidt, M.; Nahrstedt, A. Is the alkaloid pipermethystine connected with the claimed liver toxicity of Kava products? Pharmazie 2008, 63, 71–74. [PubMed]
113. Tang, J.; Dunlop, R.A.; Rowe, A.; Rodgers, K.J.; Ramzan, I. Kavalactones Yangonin and Methysticin induce apoptosis in human hepatocytes (HepG2) in vitro. Phytother. Res. 2011, 25, 417–423. [CrossRef] [PubMed]
114. Zhou, P.; Gross, S.; Liu, J.H.; Yu, B.Y.; Feng, L.L.; Nolta, J.; Sharma, V.; Piwnica-Worms, D.; Qiu, S.X. Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-_B and MAPK signaling pathways. FASEB J. 2010, 24, 4722–4732. [CrossRef] [PubMed]
115. Lude, S.; Torok, M.; Dieterle, S.; Jaggi, R.; Buter, K.B.; Krahenbuhl, S. Hepatocellular toxicity of kava leaf and root extracts. Phytomedicine 2008, 15, 120–131. [CrossRef] [PubMed]
116. Jhoo, J.W.; Freeman, J.P.; Heinze, T.M.; Moody, J.D.; Schnackenberg, L.K.; Beger, R.D.; Dragull, K.; Tang, C.S.; Ang, C.Y. In vitro cytotoxicity of nonpolar constituents from different parts of kava plant (Piper methysticum). J. Agric. Food Chem. 2006, 54, 3157–3162. [CrossRef] [PubMed]
117. Eskander, R.N.; Randall, L.M.; Sakai, T.; Guo, Y.; Hoang, B.; Zi, X. Flavokawain B, a novel, naturally occurring chalcone, exhibits robust apoptotic effects and induces G2/M arrest of a uterine leiomyosarcoma cell line. J. Obstet. Gynaecol. Res. 2012, 38, 1086–1094. [CrossRef] [PubMed]
118. Narayanapillai, S.C.; Leitzman, P.; O’Sullivan, M.G.; Xing, C. Flavokawains A and B in kava, not dihydromethysticin, potentiate acetaminophen-induced hepatotoxicity in C57BL/6 mice. Chem. Res. Toxicol. 2014, 27, 1871–1876. [CrossRef] [PubMed]
119. Martin, A.C.; Johnston, E.; Xing, C.; Hegeman, A.D. Measuring the chemical and cytotoxic variability of commercially available kava (Piper methysticum G. Forster). PLoS ONE 2014, 9, e111572. [CrossRef] [PubMed]
120. Lebot, V.; Do, T.K.; Legendre, L. Detection of flavokavins (A, B, C) in cultivars of kava (Piper methysticum) using high performance thin layer chromatography (HPTLC). Food Chem. 2014, 151, 554–560. [CrossRef] [PubMed]
121. Li, X.; Xu, X.; Ji, T.; Liu, Z.; Gu, M.; Hoang, B.H.; Zi, X. Dietary feeding of Flavokawain A, a Kava chalcone, exhibits a satisfactory safety profile and its association with enhancement of phase II enzymes in mice. Toxicol. Rep. 2014, 1, 2–11. [PubMed]
122. Singh, Y.N.; Devkota, A.K. Aqueous kava extracts do not affect liver function tests in rats. Planta Med. 2003, 69, 496–469. [PubMed]
123. Clayton, N.P.; Yoshizawa, K.; Kissling, G.E.; Burka, L.T.; Chan, P.C.; Nyska, A. Immunohistochemical analysis of expressions of hepatic cytochrome P450 in F344 rats following oral treatment with kava extract. Exp. Toxicol. Pathol. 2007, 58, 223–236. [CrossRef] [PubMed]
124. Mills, S.; Bone, K. The Essential Guide to Herbal Safety; Elsevier Inc.: Philadelphia, PA, USA, 2005; Available online: https://books.google.it/books?id=85M0N8UioCcC&pg=PA197&lpg=PA197&dq=is+kava+really+hepatotoxic?&source=bl&ots=nrZVROjep&sig=EEFj0MpPOFqvXTJu81BlwMB6jHA&hl=it&sa=X&ved=0ahUKEwjI6L2KlrvLAhXIVRQKHQA2DCwQ6AEINzAE#v=onepage&q=is%20kava%20really%20hepatotoxic%3F&f=false (accessed on 27 December 2015).
125. Unimuenster. Available online: http://www.uni-muenster.de/imperia/md/content/pharmazeutische_biologie/_v/review.pdf (accessed on 22 December 2015).
126. Whittaker, P.; Clarke, J.J.; San, R.H.; Betz, J.M.; Seifried, H.E.; de Jager, L.S.; Dunkel, V.C. Evaluation of commercial kava extracts and kavalactone standards for mutagenicity and toxicity using the mammalian cell gene mutation assay in L5178Y mouse lymphoma cells. Food Chem. Toxicol. 2008, 46, 168–174. [CrossRef] [PubMed]
127. Behl, M.; Nyska, A.; Chhabra, R.S.; Travlos, G.S.; Fomby, L.M.; Sparrow, B.R.; Hejtmancik, M.R.; Chan, P.C. Liver toxicity and carcinogenicity in F344/N rats and B6C3F1 mice exposed to Kava Kava. Food Chem. Toxicol. 2011, 49, 2820–2829. [CrossRef] [PubMed]
128. National Toxicology Program. Toxicology and carcinogenesis studies of kava kava extract (CAS No. 9000-38-8) in F344/N rats and B6C3F1 mice (Gavage Studies). Natl. Toxicol. Progr. Tech. Rep. Ser. 2012, 571, 1–186.
129. Yang, X.; Salminen, W.F. Kava extract, an herbal alternative for anxiety relief, potentiates acetaminophen-induced cytotoxicity in rat hepatic cells. Phytomedicine 2011, 18, 592–600. [CrossRef] [PubMed]
130. Lieber, C.S.; Abittan, C.S. Pharmacology and metabolism of alcohol, including its metabolic effects and interactions with other drugs. Clin. Dermatol. 1999, 17, 365–379. [CrossRef]
131. Li, A.P. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the “multiple determinant hypothesis” for the manifestation of idiosyncratic drug toxicity. Chem. Biol. Interact. 2002, 142, 7–23. [CrossRef]
132. Duffield, A.M.; Jamieson, D.D.; Lidgard, R.O.; Duffield, P.H.; Bourne, D.J. Identification of some human urinary metabolites of the intoxicating beverage kava. J. Chromatogr. 1989, 475, 273–281. [CrossRef]
133. Shen, W.W. The metabolism of psychoactive drugs: A review of enzymatic biotransformation and inhibition. Biol. Psychiatry 1997, 41, 814–826. [CrossRef]
134. Russmann, S.; Lauterburg, B.H.; Helbling, A. Kava hepatotoxicity. Ann. Intern. Med. 2001, 135, 68–69.[CrossRef] [PubMed]
135. Ingelman-Sundberg, M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity. Pharmacogenom. J. 2005, 5, 6–13. [CrossRef] [PubMed]
136. Aghdassi, A.A.; Kraft, M.; Domschke, W.; Lerch, M.M.; Weiss, F.U. Genetic polymorphisms in the UDP-glucuronosyltransferase UGT1A7 gene in patients with acute liver failure after kava-kava consumption. Arch. Toxicol. 2015, 89, 2173–2174. [CrossRef] [PubMed]
137. Wu, D.; Yu, L.; Nair, M.G.; DeWitt, D.L.; Ramsewak, R.S. Cyclooxygenase enzyme inhibitory compounds with antioxidant activities from Piper methysticum (kava kava) roots. Phytomedicine 2002, 9, 41–47. [CrossRef] [PubMed]
138. Raman, P.; Dewitt, D.L.; Nair, M.G. Lipid peroxidation and cyclooxygenase enzyme inhibitory activities of acidic aqueous extracts of some dietary supplements. Phytother. Res. 2008, 22, 204–212. [CrossRef] [PubMed]
139. Mathews, J.M.; Etheridge, A.S.; Black, S.R. Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab. Dispos. 2002, 30, 1153–1157. [CrossRef] [PubMed]
140. Zou, L.; Henderson, G.L.; Harkey, M.R.; Sakai, Y.; Li, A. Effects of kava (Kava-kava, 1Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes. Phytomedicine 2004, 11, 285–294. [CrossRef] [PubMed]
141. Cote, C.S.; Kor, C.; Cohen, J.; Auclair, K. Composition and biological activity of traditional and commercial kava extracts. Biochem. Biophys. Res. Commun. 2004, 322, 147–152. [CrossRef] [PubMed]
142. Mathews, J.M.; Etheridge, A.S.; Valentine, J.L.; Black, S.R.; Coleman, D.P.; Patel, P.; So, J.; Burka, L.T. Pharmacokinetics and disposition of the kavalactone kawain: Interaction with kava extract and kavalactones in vivo and in vitro. Drug Metab. Dispos. 2005, 33, 1555–1563. [CrossRef] [PubMed]
143. Lim, S.T.; Dragull, K.; Tang, C.S.; Bittenbender, H.C.; Efird, J.T.; Nerurkar, P.V. Effects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 rats. Toxicol. Sci. 2007, 97, 214–221. [CrossRef] [PubMed]
144. Guo, L.; Li, Q.; Xia, Q.; Dial, S.; Chan, P.C.; Fu, P. Analysis of gene expression changes of drug metabolizing enzymes in the livers of F344 rats following oral treatment with kava extract. Food Chem. Toxicol. 2009, 47, 433–442. [CrossRef] [PubMed]
145. Yamazaki, Y.; Hashida, H.; Arita, A.; Hamaguchi, K.; Shimura, F. High dose of commercial products of kava (Piper methysticum) markedly enhanced hepatic cytochrome P450 1A1 mRNA expression with liver enlargement in rats. Food Chem. Toxicol. 2008, 46, 3732–3738. [CrossRef] [PubMed]
146. Guo, L.; Shi, Q.; Dial, S.; Xia, Q.; Mei, N.; Li, Q.Z.; Chan, P.C.; Fu, P. Gene expression profiling in male B6C3F1 mouse livers exposed to kava identifies—Changes in drug metabolizing genes and potential mechanisms linked to kava toxicity. Food Chem. Toxicol. 2010, 48, 686–696. [CrossRef] [PubMed]
147. Zou, L.; Harkey, M.R.; Henderson, G.L. Synthesis, in vitro, reactivity, and identification of 6-phenyl-3-hexen-2-one in human urine after kava-kava (Piper methysticum) ingestion. Planta Med. 2005, 71, 142–146. [CrossRef] [PubMed]
148. Johnson, B.M.; Qiu, S.X.; Zhang, S.; Zhang, F.; Burdette, J.E.; Yu, L.; Bolton, J.L.; van Breemen, R.B. Identification of novel electrophilic metabolites of Piper methysticum Forst (Kava). Chem. Res. Toxicol. 2003, 16, 733–740. [CrossRef] [PubMed]
149. Zenger, K.; Agnolet, S.; Schneider, B.; Kraus, B. Biotransformation of Flavokawains A, B, and C, Chalcones from Kava (Piper methysticum), by Human Liver Microsomes. J. Agric. Food Chem. 2015, 63, 6376–6385.[CrossRef] [PubMed]
150. Rowe, A.; Ramzan, I. Are mould hepatotoxins responsible for kava hepatotoxicity? Phytother. Res. 2012, 26, 1768–1770. [CrossRef] [PubMed]
151. Teschke, R.; Sarris, J.; Lebot, V. Contaminant hepatotoxins as culprits for kava hepatotoxicity—Fact or fiction? Phytother. Res. 2013, 27, 472–474. [CrossRef] [PubMed]
152. Zhang, L.Y.; Rowe, A.; Ramzan, I. Does inflammation play a role in kava hepatotoxicity? Phytother. Res. 2011, 25, 629–630. [PubMed]
153. Zhang, L.; Rowe, A.; Braet, F.; Ramzan, I. Macrophage depletion ameliorates kavalactone damage in the isolated perfused rat liver. J. Toxicol. Sci. 2012, 37, 447–453. [CrossRef] [PubMed]
154. Gow, P.J.; Connelly, N.J.; Hill, R.L.; Crowley, P.; Angus, P.W. Fatal fulminant hepatic failure induced by a natural therapy containing kava. Med. J. Aust. 2003, 178, 442–443. [PubMed]
155. Escher, M.; Desmeules, J.; Giostra, E.; Mentha, G. Hepatitis associated with Kava, a herbal remedy for anxiety. BMJ 2001, 322, 1097. [CrossRef]
156. Campo, J.V.; McNabb, J.; Perel, J.M.; Mazariegos, G.V.; Hasegawa, S.L.; Reyes, J. Kava-induced fulminant hepatic failure. J. Am. Acad. Child Adolesc. Psychiatry 2002, 41, 631–632. [CrossRef] [PubMed]
157. Estes, J.D.; Stolpman, D.; Olyaei, A.; Corless, C.L.; Ham, J.M.; Schwartz, J.M.; Orloff, S.L. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch. Surg. 2003, 138, 852–858. [CrossRef] [PubMed]
158. Stickel, F.; Baumuller, H.M.; Seitz, K.; Vasilakis, D.; Seitz, G.; Seitz, H.K.; Schuppan, D. Hepatitis induced by Kava (Piper methysticum rhizoma). J. Hepatol. 2003, 39, 62–67. [CrossRef]
159. Humberston, C.L.; Akhtar, J.; Krenzelok, E.P. Acute hepatitis induced by kava kava. J. Toxicol. Clin. Toxicol. 2003, 41, 109–113. [CrossRef] [PubMed]
160. Teschke, R.; Gaus, W.; Loew, D. Kava extracts: Safety and risks including rare hepatotoxicity. Phytomedicine 2003, 10, 440–446. [CrossRef] [PubMed]
161. Christl, S.U.; Seifert, A.; Seeler, D. Toxic hepatitis after consumption of traditional kava preparation. J. Travel Med. 2009, 16, 55–56. [CrossRef] [PubMed]
162. Scribd. Available online: http://www.scribd.com/doc/46179789/Cytotoxicity-of-Extract-of-Malaysian-Mitragyna-Speciosa-Korth-and-Its-Dominant-Alkaloid Mitragynine#scribd (accessed on 4 January 2016).
163. Moklas, M.A.M.; Nurul Raudzah, A.R.; Taufik Hidayat, M.; Sharida, F.; Farah Idayu, N.; Zulkhairi, A.; Shamima, A.R. A preliminary toxicity study of mitragynine, an alkaloid from Mitragyna speciosa Korth and its effects on locomotor activity in rats. Adv. Med. Dent. Sci. 2008, 2, 56–60.
164. Ghazali, A.R.; Abdullah, R.; Ramli, N.; Rajab, N.F.; Ahmad-Kamal, M.S.; Yahya, N.A. Mutagenic and antimutagenic activities of Mitragyna speciosa Korth extract using Ames test. J. Med. Plants Res. 2011, 5, 1345–1348.
165. Macko, E.; Weisbach, J.A.; Douglas, B. Some observations on the pharmacology of mitragynine. Arch. Int. Pharmacodyn. Ther. 1972, 198, 145–161. [PubMed]
166. De Moraes, N.V.; Moretti, R.A.; Furr, E.B. McCurdy, C.R.; Lanchote, V.L. Determination of mitragynine in rat plasma by LC-MS/MS: Application to pharmacokinetics. J. Chromatogr. B 2009, 877, 2593–2597.[CrossRef] [PubMed]
167. Janchawee, B.; Keawpradub, N.; Chittrakarn, S.; Prasettho, S.; Wararatananurak, P.; Sawangjareon, K. A high-performance liquid chromatographic method for determination of mitragynine in serum and its application to a pharmacokinetic study in rats. Biomed. Chromatogr. 2007, 21, 176–183. [CrossRef] [PubMed]
168. Azizi, J.; Ismail, S.; Mordi, M.N.; Ramanathan, S.; Said, M.I.; Mansor, S.M. In vitro and in vivo effects of three different Mitragyna speciosa korth leaf extracts on phase II drug metabolizing enzymes—Glutathione transferases (GSTs). Molecules 2010, 15, 432–441. [CrossRef] [PubMed]
169. Kalix, P. Khat, an amphetamine-like stimulant. J. Psychoact. Drugs 1994, 26, 69–74. [CrossRef] [PubMed]
170. Nencini, P.; Ahmed, A.M. Khat consumption: A pharmacological review. Drug Alcohol Depend. 1989, 23, 19–29. [CrossRef]
171. Chapman, M.H.; Kajihara, M.; Borges, G.; O’Beirne, J.; Patch, D.; Dhillon, A.P.; Crozier, A.; Morgan, M.Y. Severe, acute liver injury and khat leaves. N. Engl. J. Med. 2010, 362, 1642–1644. [CrossRef] [PubMed]
172. Abid, M.D.; Chen, J.; Xiang, M.; Zhou, J.; Chen, X.; Gong, F. Khat (Catha edulis) generates reactive oxygen species and promotes hepatic cell apoptosis via MAPK activation. Int. J. Mol. Med. 2013, 32, 389–395.[PubMed]
173. Aklillu, E.; Herrlin, K.; Gustafsson, L.L.; Bertilsson, L.; Ingelman-Sundberg, M. Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. Pharmacogenetics 2002, 12, 375–383. [CrossRef] [PubMed]
174. Cascorbi, I. Pharmacogenetics of cytochrome p4502D6: Genetic background and clinical implication. Eur. J. Clin. Investig. 2003, 33 (Suppl. S2), 17–22. [CrossRef]
175. Pedersen, A.J.; Reitzel, L.A.; Johansen, S.S.; Linnet, K. In vitro metabolism studies on mephedrone and analysis of forensic cases. Drug Test. Anal. 2013, 5, 430–438. [CrossRef] [PubMed]
176. Pedersen, A.J.; Petersen, T.H.; Linnet, K. In vitro metabolism and pharmacokinetic studies on methylone. Drug Metab. Dispos. 2013, 41, 1247–1255. [CrossRef] [PubMed]
177. Bedada, W.; de Andres, F.; Engidawork, E.; Pohanka, A.; Beck, O.; Bertilsson, L.; Llerena, A.; Aklillu, E. The Psychostimulant khat (Catha edulis) Inhibits CYP2D6 enzyme activity in humans. J. Clin. Psychopharmacol. 2015, 35, 694–699. [CrossRef] [PubMed]
178. Teschke, R. Kava hepatotoxicity: Pathogenetic aspects and prospective considerations. Liver Int. 2010, 30, 1270–1279. [CrossRef] [PubMed]
179. Kuchta, K.; Schmidt, M.; Nahrstedt, A. German kava ban lifted by court: The alleged hepatotoxicity of kava (Piper methysticum) as a case of ill-defined herbal drug identity, lacking quality control, and misguided regulatory politics. Planta Med. 2015, 81, 1647–1653. [CrossRef] [PubMed]
180. Herbalgram. Available online: http://cms.herbalgram.org/heg/volume11/07July/GermanKavaBanReversal.html?ts=1457796407&signature=f5ff90a5a274ae67fa1fc62f1ed7ee40%3Cspan&ts=1458062348&signature=91d4418f692013ef2178b44d285f2169 (accessed on 13 March 2016).
181. Savage, K.M.; Stough, C.K.; Byrne, G.J.; Scholey, A.; Bousman, C.; Murphy, J.; Macdonald, P.; Suo, C.; Hughes, M.; Thomas, S.; et al. Kava for the treatment of generalised anxiety disorder (K-GAD): Study protocol for a randomised controlled trial. Trials 2015, 16. [CrossRef] [PubMed]